BTK Inhibitor Combination Therapy for CLL: Weighing the Benefits and Trade-Offs

“There are pros and cons to each,” Dr. Tilal Hilal, a hematologist at Mayo Clinic Arizona in Phoenix, tells SurvivorNet.

How Combination Therapy Works

BTK inhibitors block signals that chronic lymphocytic leukemia cells rely on to survive and grow. Venetoclax works differently, targeting a protein called BCL-2 that helps cancer cells avoid dying. By attacking CLL through two different mechanisms, the combination can produce deep and lasting responses.

“The most common combination with a BTK inhibitor now is venetoclax, a BCL-2 inhibitor,” Dr. Hilal explains.

Venetoclax has been used for years to treat CLL, often alongside an anti-CD20 monoclonal antibody, an intravenous therapy that helps the immune system recognize and destroy the B cells causing leukemia.

“We can use it in combination with monoclonal antibody infusion… something like rituximab or a more effective one is obinutuzumab,” Dr. Hilal says.

More recently, the U.S. Food and Drug Administration approved a combination of the BTK inhibitor acalabrutinib (Calquence) and venetoclax, giving patients another effective first-line treatment option.

How Long Do I Take This Treatment?

For many patients, the biggest distinction between the two approaches isn’t how well they work—it’s how long treatment lasts.

“When you start a covalent BTK inhibitor in patients, you’re not planning on stopping it,” Dr. Hilal explains. “It’s designed to be given indefinitely.”

That means patients continue taking the medication as long as it’s controlling the disease and side effects remain manageable.

The combination approach is different.

“When you combine it with BCL-2 inhibitor venetoclax, it’s often given for about one year in combination,” he says.

Because treatment has a planned end date, doctors refer to it as a fixed-duration or time-limited therapy.

“And so it provides a time-limited treatment approach.”

The Pros of Fixed-Duration Therapy

For many patients, knowing treatment is expected to end after about a year is an appealing option.

Instead of taking medication indefinitely, patients complete a planned course of therapy and then enter a period of observation while doctors monitor for any signs the disease is returning.

This treatment-free interval can be attractive for patients who prefer not to remain on daily medication long term.

The Trade-Offs

Combination therapy also comes with some additional considerations.

“Do you want to take two pills for a year?” Dr. Hilal asks. “Do you want to take one pill indefinitely?”

Using two targeted therapies together may increase the likelihood of certain side effects, particularly low blood cell counts caused by bone marrow suppression.

“There are other risks like effects on the blood counts, bone marrow suppression,” he says. “Usually when you combine two oral therapies, that becomes a little bit more pronounced.”

Even so, Dr. Hilal says the combination remains highly manageable for most patients.

“For the most part, it’s pretty well tolerated and has become a very important treatment option.”

There’s No One ‘Right’ Choice

Although both approaches are highly effective, Dr. Hilal says there isn’t a specific type of patient who automatically belongs in one treatment group or the other.

“I don’t know if I would have a certain patient in mind that I would say for sure requires this approach versus the other approach,” he says.

Instead, choosing a treatment involves weighing several practical factors alongside the medical considerations.

“I think a lot of times it’s a conversation that takes into account ease of starting the treatment, logistics, where the patient lives,” Dr. Hilal explains.

Doctors also consider each patient’s preferences and daily routine.

“Are they the kind of person who likes to take more pills or is willing to take more pills—or less pills?”

Shared Decision-Making Is Key

Advances in targeted therapies have given people with CLL more options than ever before. Whether someone chooses continuous treatment with a BTK inhibitor or a fixed-duration combination with venetoclax, both approaches can provide excellent disease control.

Rather than searching for a universally “best” treatment, Dr. Hilal encourages patients to have an open discussion with their healthcare team about what matters most to them—whether that’s limiting the length of treatment, minimizing medications, reducing office visits, or fitting therapy into their lifestyle.

For many patients, the best treatment isn’t simply the one that’s most effective—it’s the one that best aligns with their goals, preferences, and day-to-day life.

Questions to Ask Your Doctor

• Am I a candidate for a BTK inhibitor alone or combination therapy?
• What are the benefits of a fixed-duration treatment compared with continuous therapy?
• How long would I be expected to stay on each treatment option?
• What side effects are more common with combination therapy?
• How often will I need blood tests or follow-up visits?
• If I choose a fixed-duration treatment, what happens after I finish therapy?
• If one treatment stops working, what options would I have next?

Learn more about SurvivorNet's rigorous medical review process.